October 18, 2018 / 5:36 AM / a month ago

BRIEF-Novartis To Buy Endocyte In $2.1 Bln Deal

Oct 18 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES PLANNED ACQUISITION OF ENDOCYTE TO EXPAND EXPERTISE IN RADIOPHARMACEUTICALS AND BUILD ON COMMITMENT TO TRANSFORMATIONAL THERAPEUTIC PLATFORMS

* NOVARTIS ANNOUNCES PLANNED ACQUISITION OF ENDOCYTE TO EXPAND EXPERTISE IN RADIOPHARMACEUTICALS AND BUILD ON COMMITMENT TO TRANSFORMATIONAL THERAPEUTIC PLATFORMS

* ACQUISITION WOULD ADD (177)LU-PSMA-617, A POTENTIAL FIRST-IN-CLASS RADIOLIGAND THERAPY IN PHASE III DEVELOPMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

* WOULD ACQUIRE ALL OUTSTANDING SHARES OF ENDOCYTE COMMON STOCK FOR USD 24 PER SHARE. THIS OFFER VALUES ENDOCYTE’S EQUITY AT USD 2.1 BILLION

* OFFER VALUES ENDOCYTE’S EQUITY AT USD 2.1 BILLION

* ACQUISITION OF ENDOCYTE IS PLANNED TO BE FUNDED THROUGH AVAILABLE CASH Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below